(Q43039938)

12 November 2017

Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. (English)

1 reference

12 November 2017

0 references

3

K Rajender Reddy

1 reference

12 November 2017

2

Jennifer E Layden

1 reference

12 November 2017

Thomas J Layden

1

1 reference

12 November 2017

Rachel S Levy-Drummer

series ordinal

4

1 reference

12 November 2017

Jennifer Poulakos

series ordinal

5

1 reference

12 November 2017

Avidan U Neumann

series ordinal

6

1 reference

12 November 2017

1 September 2002

1 reference

Journal of Viral Hepatitis

12 November 2017

1 reference

12 November 2017

9

1 reference

12 November 2017

5

1 reference

12 November 2017

334-339

1 reference

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

12 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00376.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00376.X

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00376.X

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00376.X

A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00376.X

21 January 2018

Letters to the Editor

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00376.X

Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00376.X

Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00376.X

Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00376.X

Early predictors of response to treatment in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00376.X

Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00376.X

Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00376.X

10.1046/J.1365-2893.2002.00376.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference